

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for March 2026

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Laboratoire Riva Inc.	Riva-Cyproterone	Androcur	CYPROTERONE ACETATE	50 mg	tablet	02395797
Jamp Pharma Corporation	Jamp Deferasirox (Type J)	Jadenu	DEFERASIROX	90 mg	tablet	02549832
Jamp Pharma Corporation	Jamp Deferasirox (Type J)	Jadenu	DEFERASIROX	180 mg	tablet	02549840
Jamp Pharma Corporation	Jamp Deferasirox (Type J)	Jadenu	DEFERASIROX	360 mg	tablet	02549859
Auro Pharma Inc.	Auro-Mirabegron	Myrbetriq	MIRABEGRON	50 mg	ER tablet	02564955
Apotex Inc.	Apo-Mirabegron	Myrbetriq	MIRABEGRON	25 mg	ER tablet	02564963
Apotex Inc.	Apo-Mirabegron	Myrbetriq	MIRABEGRON	50 mg	ER tablet	02564971